Ethics around businesses marketing unproven and unlicensed COVID-19 stem-cell-based “therapies”

May 7, 2020

"As the public looks for treatments for SARS-CoV-2, some businesses in the United States are marketing unlicensed and unproven stem-cell-based “therapies” and exosome products that claim to prevent or treat the disease. In a recent journal article in Cell Stem Cell, University of Minnesota bioethicist Leigh Turner studied how companies are capitalizing on the pandemic by promoting unproven methods of stem-cell-based treatment. There is a history of private clinics pushing unlicensed and non-evidence-based interventions for injuries and illnesses."